

## 7th. European Seminars in Virology (EuSeV) 2019 Program

<b>FRIDAY 14.06.2019</b>	
<b>13:45-14:00</b>	<b>Welcome</b> <b>Dana Wolf, Gabriella Campadelli-Fiume, Thomas Mertens, Michael Kann Giorgio Palù</b>
<b>Session on Ethical and technological issues about antiviral vaccine and antibodies development Chair: Giorgio Palù</b>	
<b>14:00-14:40</b>	Andrea Grignolio, Cognitive bases for vaccine hesitancy Medical Humanities & Bioethics, Vita-Salute San Raffaele University, Milan, Italy grignolio.andrea@hsr.it
<b>14:40-15:20</b>	Rino Rappuoli, Reverse vaccinology 2.0 GSK, Siena, Italy rino.r.rappuoli@gsk.com
<b>15:20-16:00</b>	Mel Kohn, Anti-Ebola vaccines Regional Director of Medical Affairs Lead for Vaccines, Europe at Merck/MSD Vaccins melvin.kohn@msd.com
<b>16:00-16:30</b>	Discussion
<b>16:30-17:30</b>	Selected oral presentations
<b>17:30-18:00</b>	<b>DISCUSSIONS IN FRONT OF POSTERS</b>
<b>20:00 Dinner</b>	

<b>SATURDAY 15.06.2019</b>	
<b>Regulatory and technological issues about antiviral vaccine and antibodies development</b>	
<b>Chair: Thomas Mertens &amp; Gabriella Campadelli Fiume</b>	
<b>09:00-09:40</b>	Guido Silvestri, Towards an HIV vaccine: recent advances from studies in non-human primates Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, USA, gsilves@emory.edu
<b>09:40-10:20</b>	Christian Sinzger, CMV-Elite-neutralizing Antibodies Institute of Virology, University of Ulm, Ulm, Germany, christian.sinzger@uniklinik-ulm.de
<b>10:20-11:00</b>	Gabriella Campadelli Fiume, Viruses as vectors of antigen agnostic vaccine Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy, gabriella.campadelli@unibo.it
<b>11:00-11:30</b>	<b>Break</b>
<b>11:30-12:10</b>	Thomas Mertens, The art of vaccine recommendations in the real world Institute of Virology, Ulm University Medical Center, Ulm, Germany, thomas.mertens@uni-ulm.de
<b>12:10-13:10</b>	<b>Selected oral presentations</b>
<b>13:15-15:00</b>	<b>Lunch break</b>

<b>Development of vaccines and antibodies against viral infection</b>	
<b>Chair: Dana Wolf</b>	
<b>15:00-15:40</b>	Ali Mirazimi, Development of vaccine against Crimean Congo Hemorrhagic Fever; Past and Future Department of Laboratory Medicine, Karolinska University Hospital and KI, Stockholm, Sweden. Ali.Mirazimi@ki.se
<b>15:40-16:20</b>	Arnaud Marchant, Maternal and neonatal immunization Institute for Medical Immunology, Université Libre de Bruxelles, Brussels, Belgium, arnaud.marchant@ulb.ac.be
<b>16:20-17:00</b>	Frédéric Tangy, Vaccines against Ebolavirus and other emerging viruses Viral Genomics and Vaccination Unit, Institut Pasteur, Paris, France, ftangy@pasteur.fr
<b>17:00-17:20</b>	<b>Break</b>
<b>17:20-18:00</b>	Florian Klein, HIV-Super-neutralizing Antibodies Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany. florian.klein@uk-koeln.de
<b>18:00-19:00</b>	Selected oral Presentations
<b>20:00 Dinner</b>	

<b>SUNDAY 16.06.2019</b>	
<b>Success and failure of antiviral vaccine development</b>	
<b>Chair: Michael Kann</b>	
<b>9:00-9:40</b>	John J. Skehel, Experimental uses and roles in immunity of antibodies that recognize influenza haemagglutinin Francis Crick Institute, London, UK, John.Skehel@crick.ac.uk
<b>09:40-10:20</b>	Emanuele Montomoli, Present and future of anti-influenza vaccinations Department of Molecular and Developmental Medicine, University of Siena, Italy, Emanuele.montomoli@unisi
<b>10:20-11:00</b>	Wolfgang Hammerschmidt, EBV-Vaccine Research Unit Gene Vectors, Helmholtz Zentrum München, Germany, hammerschmidt@helmholtz-muenchen.de
<b>11:00-11:40</b>	Sergio Abrignani, Why is it too difficult to develop a vaccine against HCV INGM, Milan, Italy, abrignani@ingm.org
<b>11:40-12:20</b>	Giorgio Palù, Clinically and experimentally adopted vaccines against Dengue, Zika virus and West Nile virus Department of Molecular Medicine, University of Padova, Italy, giorgio.palu@unipd.it
<b>12:20 Closing Remarks and Brunch</b>	